Home/Pipeline/Kerendia® (finerenone)

Kerendia® (finerenone)

Chronic Kidney Disease in Type 2 Diabetes

Phase IIIActive, recruitingNCT05374265

Key Facts

Indication
Chronic Kidney Disease in Type 2 Diabetes
Phase
Phase III
Status
Active, recruiting
Company

About Bayer

Bayer AG's mission is 'Health for all, Hunger for none,' focusing on advancing healthcare and food security through science-led innovation. The company has achieved significant scale and diversification, most notably through the transformative acquisition of Monsanto, establishing a leading position in agricultural sciences. Its strategy centers on driving growth in its core pharmaceutical pipeline—particularly in oncology, cardiology, and cell & gene therapy—while navigating legacy legal challenges and optimizing its portfolio to enhance shareholder value and operational focus.

View full company profile